Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis

Journal of Cutaneous Pathology

Volumn 34, Issue 4, 2007, Pages 289-295

  Sundram, Uma N ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD2 ANTIGEN; CHLORDANE; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOSIALIN; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYELOPEROXIDASE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TOLONIUM CHLORIDE; TRYPTASE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CUTANEOUS MAST CELL DISEASE; CYTOCHEMISTRY; DISEASE MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; MYELOID LEUKEMIA; MYELOID LEUKEMIA CUTIS; SKIN DISEASE; STAINING;

ANTIGENS, CD; ANTIGENS, CD2; ANTIGENS, CD43; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID; MAST CELLS; MASTOCYTOSIS, CUTANEOUS; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; PROTO-ONCOGENE PROTEINS C-KIT; TRYPTASES;

EID: 33947510125     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00602.x     Document Type: Article

References (25)

1. Valent P, Horny HP, Li CY, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H et al., eds. Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press, 2001; 293.
2. Li WV, Kapadia SB, Sonmez-Alpan E, et al. Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase, CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996; 9: 982.
3. Yang F, Tran T, Carlson JA, et al. Paraffin section immunophenotype of cutaneous and extracutaneous mast cell disease. Comparison to other hematopoietic neoplasms. Am J Surg Pathol 2000; 24: 703.
4. Natkunam Y, Rouse RV. Utility of paraffin section immunohistochemistry for C-KIT (CD117) in the differential diagnosis of systemic mast cell disease involving the bone marrow. Am J Surg Pathol 2000; 24: 81.
5. Sotlar K, Horny HP, Simonitsch I, et al. CD25 indicates the neoplastic phenotype of mast cells. A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004; 28: 1319.
6. Horny HP, Sillaber C, Menke D, et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998; 22: 1132.
7. King R, Peterson AC, Peterson KC, et al. Microphthalmia transcription factor expression in cutaneous mast cell disease. Am J Dermatopathol 2002; 24: 282.
8. Morii E, Oboki K, Ishihara K, et al. Roles of MITF for development of mast cells in mice: effects on both precursors and tissue enviroments. Blood 2004; 104: 1656.
9. King R, Weilbaecher KN, McGill G, et al. Microphthalmia transcription factor: a sensitive and specific melanocyte marker for melanoma diagnosis. Am J Pathol 1999; 155: 731.
10. Florenzano F, Bentivoglio M. Degranulation, density, and distribution of mast cells in the rat thalamus: a light and electron microscopic study in basal conditions and after intracerebroventricular administration of nerve growth factor. J Comp Neurol 2000; 424: 651.
11. Gotlib J, Berube C, Growney JD, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 2005; 106: 2865.
12. Sperr WR, Jordan J, Baghestanian M, et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001; 98: 2200.
13. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002; 43: 2257.
14. Sperr WR, Mitterbauer M, Mitterbauer G, et al. Quantitation of minimal residual disease in acute myeloid leukemia by tryptase monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005; 11: 6536.
15. Busam KJ, Iversen K, Coplan KC, et al. Analysis of microphthalmia transcription factor expression in normal tissues and tumors, and comparison of its expression with S-100 protein, gp100, and tyrosinase in desmoplastic malignant melanoma. Am J Surg Pathol 2001; 25: 197.
16. Miettinen M, Fernandez M, Franssila K, et al. Microphthalmia transcription factor in the immunohistochemical diagnosis of metastatic melanoma. Comparison with four other melanoma markers. Am J Surg Pathol 2001; 25: 205.
17. Seethala RR, Goldblum JR, Hicks DG, et al. Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions. Mod Pathol 2004; 17: 1491.
18. Stevens EC, Rosenthal NS. Bone marrow mast cell morphologic features and hematopoietic dyspoiesis in systemic mast cell disease. Am J Clin Pathol 2001; 116: 177.
19. Noack F, Sotlar K, Notter M, et al. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V. Leuk Lymphoma 2004; 45: 2295.
20. Escribano L, Diaz-Augustin B, Bravo P, et al. Immunophenotype of bone marrow mast cells in indolent systemicmast cell disease in adults. Leuk Lymphoma 1999; 25: 227.
21. Pardanani A, Kimlinger T, Reeder T, et al. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004; 28: 777.
22. Chott A, Guenther P, Huebner A, et al. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma. Am J Surg Pathol 2003; 27: 1013.
23. Horny HP, Valent P. Histopathologic and immunohistochemical aspects of mastocytosis. Int Arch Allergy Immunol 2002; 127: 115.
24. Rosenfeld C, Kantarjian H. Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies. Leuk Lymphoma 2001; 41: 493.
25. Byrd JC, Edenfield WJ, Shields DJ, et al. Extramedullary myeloid cell tumors in acute nonlymphocytic leukemia: a clinical review. J Clin Oncol 1995; 13: 1800.